Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
BeOne Medicines
Astellas Pharma Inc
Faron Pharmaceuticals Ltd
CellCentric Ltd.
Incyte Corporation
Incyte Corporation
Novartis
Ellipses Pharma
Molecular Partners AG
Ascentage Pharma Group Inc.
Aptose Biosciences Inc.
Sanofi
AbbVie
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Treadwell Therapeutics, Inc
Servier
Sumitomo Pharma America, Inc.
Akeso
Arog Pharmaceuticals, Inc.
Servier
Akeso
Novartis
Ascentage Pharma Group Inc.
Novo Nordisk A/S
Sumitomo Pharma America, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Actinium Pharmaceuticals
GlaxoSmithKline
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Maxinovel Pty., Ltd.
Traws Pharma, Inc.
Novartis
Incyte Corporation
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)